Format

Send to

Choose Destination
See comment in PubMed Commons below
J Am Acad Dermatol. 2015 Jun;72(6):1010-5.e5. doi: 10.1016/j.jaad.2015.01.003.

Hematopoietic stem cell transplantation for primary cutaneous γδ T-cell lymphoma and refractory subcutaneous panniculitis-like T-cell lymphoma.

Author information

1
Yale School of Medicine, New Haven, Connecticut. Electronic address: Juliet.gibson@yale.edu.
2
Department of Medical Oncology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania.
3
Department of Dermatology and Pathology, Yale University School of Medicine, New Haven, Connecticut.
4
Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut.
5
Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, Connecticut.
6
Hematology and Bone Marrow Transplantation, Yale University School of Medicine, New Haven, Connecticut.

Abstract

BACKGROUND:

The panniculitic T-cell lymphomas (TCLs) comprise 2 distinct entities, αβ subcutaneous panniculitis-like TCL (SPTCL) and the γδ cutaneous TCLs with pannicular involvement primary cutaneous γδ (PCGD)-TCL. Although outcomes for most patients with SPTCL are favorable, those with PCGD-TCLs generally have an inferior outcome, and treatment strategies have not been well defined. Allogeneic hematopoietic stem cell transplantation (HSCT) has been shown to be a potentially curative strategy in aggressive TCLs and in refractory and advanced-stage mycosis fungoides.

OBJECTIVE:

We sought to analyze the outcomes of HSCT for panniculitic cutaneous TCL.

RESULTS:

Fourteen patients (4 SPTCL, 10 PCGD-TCL) presented with primarily pannicular T-cell infiltrates. Seven patients underwent allogeneic HSCT from matched-related donors and matched-unrelated donors of which 4 (57%) are alive (1 SPTCL, 3 PCGD-TCL) at 7.8, 6.9, 6.2, and 0.25 years. Two patients underwent autologous HSCT (1 SPTCL, 1 PCGD-TCL) and both are alive at a median follow-up of 1.91 years.

LIMITATIONS:

This study is limited by its retrospective nature and small sample size because of the rarity of SPTCL and PCGD-TCL.

CONCLUSION:

Aggressive therapy followed by allogeneic HSCT is a promising treatment modality for patients with PCGD-TCL.

KEYWORDS:

T-cell lymphoma; hematopoietic stem cell transplantation; primary cutaneous γδ T-cell lymphoma; subcutaneous panniculitis-like T-cell lymphoma; γ-δ

PMID:
25981001
DOI:
10.1016/j.jaad.2015.01.003
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center